HemaQuest Names New CEO

11/16/10

HemaQuest Pharmaceuticals, the developer of new treatments for blood diseases, has named John Longenecker as its new CEO, replacing Ron Berenson, according to a report in TechFlash. Longenecker was formerly the CEO of San Diego-based Favrille, the developer of an immune boosting therapy for cancer. HemaQuest will now likely have offices in San Diego and Seattle, Longenecker said in an e-mail to TechFlash. HemaQuest most recently made news when it closed on a $16 million financing round in July.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Next Post

Related Topics

Related Posts

    

Xconomy Events Across the Network

The Napa Summit: Keeping America Growing

San Francisco · 6/7/12

More Xconomy Events

Xconomy’s Most Popular

  1. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  2. Biotech IPOs Start to Show Some Modest Signs of Life
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story
  5. Announcing Xconomy’s Napa Summit: Keeping America Growing

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.